BNT162

  • BNT162, a mRNA-based coronavirus vaccine, is being co-developed by Pfizer and BioNTech. It is expected to enter clinical testing in April 2020. BioNTech is also collaborating with Fosun Pharma to develop BNT162 for China.

  • You must be logged in to reply to this topic.